Pharmaceutical Supply chain Risk Assessment During COVID-19 Epidemic

新冠疫情期间药品供应链风险评估

阅读:2

Abstract

The global health products supply chain is negatively influenced by the COVID-19 pandemic. Moreover, the risks in the pharmaceutical supply chain (PSC) have increased. Assessment and mitigation risks in PSC are essential issues to control and counter these risks. In this study, a 2-Tuple ARAS-BWM approach, which combines ARAS and BWM methods under linguistic 2-Tuple environment, is proposed to evaluate and address various risks to the best mitigation strategies in the pharmaceutical industry in Tunisia during COVID-19. Noted that the main risk identified in the PSC is related to supply and suppliers and its best mitigation strategy is reducing risk.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。